CO5550419A2 - Novedosos inhibidores de la gama secretasa - Google Patents
Novedosos inhibidores de la gama secretasaInfo
- Publication number
- CO5550419A2 CO5550419A2 CO04003799A CO04003799A CO5550419A2 CO 5550419 A2 CO5550419 A2 CO 5550419A2 CO 04003799 A CO04003799 A CO 04003799A CO 04003799 A CO04003799 A CO 04003799A CO 5550419 A2 CO5550419 A2 CO 5550419A2
- Authority
- CO
- Colombia
- Prior art keywords
- new inhibitors
- alkyl
- range
- secret range
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Abstract
1.- Esta invención describe novedosos inhibidores de la gama secretasa de la fórmula:en el cual: R1 es un grupo arilo o heteroarilo sustituido; R2 es un grupo R1 grupo alquilo, -X(CO)Y, -(CR32)1-4X(CO)Y; cada R3A es independientemente H o alquilo; X es -O-, -NH o -N-alquilo e Y es -NR6R7 o - N(R3)(CH2)2-6NR6R7.También se describe un método para el tratamiento de la Enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31001301P | 2001-08-03 | 2001-08-03 | |
US35551002P | 2002-02-06 | 2002-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5550419A2 true CO5550419A2 (es) | 2005-08-31 |
Family
ID=26977148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04003799A CO5550419A2 (es) | 2001-08-03 | 2004-01-21 | Novedosos inhibidores de la gama secretasa |
Country Status (19)
Country | Link |
---|---|
US (1) | US6683091B2 (es) |
EP (1) | EP1492765B1 (es) |
JP (1) | JP4418671B2 (es) |
KR (1) | KR20040019094A (es) |
CN (1) | CN1304390C (es) |
AR (1) | AR034390A1 (es) |
AT (1) | ATE515495T1 (es) |
AU (1) | AU2002324582B9 (es) |
BR (1) | BR0211698A (es) |
CA (1) | CA2455863C (es) |
CO (1) | CO5550419A2 (es) |
HU (1) | HUP0600673A3 (es) |
IL (1) | IL159848A0 (es) |
MX (1) | MXPA04001014A (es) |
NO (1) | NO20040933L (es) |
PL (1) | PL372212A1 (es) |
RU (1) | RU2004106540A (es) |
TW (1) | TWI242555B (es) |
WO (1) | WO2003014075A2 (es) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
WO2003032994A2 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
CN100562516C (zh) | 2001-12-27 | 2009-11-25 | 第一制药株式会社 | β-淀粉样蛋白产生和分泌的抑制剂 |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
EP1640366A4 (en) | 2003-06-30 | 2009-05-13 | Daiichi Seiyaku Co | HETEROCYCLES METHYLSULFON DERIVATIVE |
CA2534950A1 (en) * | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
JP4472700B2 (ja) * | 2003-08-08 | 2010-06-02 | シェーリング コーポレイション | 複素環置換基を有する環状アミンbase−1阻害剤 |
JP2007526455A (ja) * | 2004-02-03 | 2007-09-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法 |
CN1950518A (zh) | 2004-02-03 | 2007-04-18 | 密执安州立大学董事会 | 表征、调节、诊断和治疗癌症的组合物和方法 |
WO2005097768A2 (en) * | 2004-04-05 | 2005-10-20 | Schering Corporation | Novel gamma secretase inhibitors |
CA2567343A1 (en) * | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
ATE461926T1 (de) * | 2004-06-30 | 2010-04-15 | Schering Corp | Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer |
ATE491693T1 (de) * | 2004-07-22 | 2011-01-15 | Schering Corp | Substituierte amide als inhibitoren der beta- sekretase |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
AR056865A1 (es) * | 2005-06-14 | 2007-10-31 | Schering Corp | Heterociclos nitrogenados y su uso como inhibidores de proteasas, composiciones farmaceuticas |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
ES2547421T3 (es) | 2005-10-31 | 2015-10-06 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para diagnosticar y tratar el cáncer |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
WO2007053648A2 (en) | 2005-10-31 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
AU2007207481B2 (en) * | 2006-01-20 | 2012-08-23 | Merck Sharp & Dohme Corp. | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors |
US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
US8133857B2 (en) | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
TW200813054A (en) * | 2006-06-02 | 2008-03-16 | Elan Pharm Inc | Fused, tricyclic sulfonamide inhibitors of gamma secretase |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008275735B2 (en) | 2007-07-05 | 2014-03-27 | Merck Sharp & Dohme Corp. | Tetrahydropyranochromene gamma secretase inhibitors |
CL2008002084A1 (es) * | 2007-07-17 | 2009-01-23 | Schering Corp | Compuestos derivados de bencensulfonil cromano, tiocromano, tetrahidronaftaleno, inhibidores de la gamma secretasa; composicion farmaceutica que lo comprende; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas |
NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
AU2009313527A1 (en) * | 2008-11-06 | 2010-05-14 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
WO2011009064A1 (en) * | 2009-07-17 | 2011-01-20 | The J. David Gladstone Institutes | Methods of controlling cell proliferation |
MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤 |
AU2011235904B2 (en) | 2010-04-01 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
JP5275315B2 (ja) * | 2010-10-01 | 2013-08-28 | 学校法人近畿大学 | 新規化合物及びβ−セクレターゼ阻害剤 |
EP2638014B1 (en) | 2010-11-08 | 2017-01-04 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2747769B1 (en) | 2011-08-22 | 2017-08-02 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
US9629891B2 (en) | 2011-10-17 | 2017-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
EP2846804B1 (en) | 2012-05-08 | 2017-11-29 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
WO2013169864A2 (en) | 2012-05-08 | 2013-11-14 | Lycera Corporation | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE |
US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
JP6728061B2 (ja) | 2014-05-05 | 2020-07-22 | リセラ・コーポレイションLycera Corporation | RORγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療 |
CN104027810B (zh) * | 2014-06-30 | 2016-02-10 | 王涛 | 一种构建先天性肝内胆管发育不良综合征动物模型的方法 |
WO2016130818A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
CA3002846A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof |
WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
EP3368539B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as ror gamma t inhibitors and uses thereof |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
EP3823672A1 (en) | 2018-07-19 | 2021-05-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Combination for treating cancer |
WO2022101481A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1328176A (fr) * | 1962-07-06 | 1963-05-24 | Monsanto Chemicals | Procédé de préparation de dérivés des hydroquinoléines |
JPS556321A (en) * | 1978-06-27 | 1980-01-17 | Konishiroku Photo Ind Co Ltd | Color photographic material |
JPS6395447A (ja) * | 1986-10-11 | 1988-04-26 | Konica Corp | 色素画像の光堅牢性が改良されたハロゲン化銀写真感光材料 |
HUP0102714A3 (en) * | 1998-07-30 | 2003-01-28 | Warner Lambert Co | Tricyclic sulfonamid derivatives as inhibitors of matrix metalloproteinases and medicaments containing the same |
NZ514453A (en) * | 1999-02-26 | 2003-04-29 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
IL138686A0 (en) * | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
AU7997600A (en) * | 1999-10-08 | 2001-04-23 | Du Pont Pharmaceuticals Company | Amino lactam sulfonamides as inhibitors of abeta protein production |
-
2002
- 2002-08-01 AT AT02759233T patent/ATE515495T1/de not_active IP Right Cessation
- 2002-08-01 RU RU2004106540/04A patent/RU2004106540A/ru not_active Application Discontinuation
- 2002-08-01 CN CNB028152603A patent/CN1304390C/zh not_active Expired - Fee Related
- 2002-08-01 JP JP2003519025A patent/JP4418671B2/ja not_active Expired - Fee Related
- 2002-08-01 CA CA2455863A patent/CA2455863C/en not_active Expired - Fee Related
- 2002-08-01 IL IL15984802A patent/IL159848A0/xx unknown
- 2002-08-01 HU HU0600673A patent/HUP0600673A3/hu unknown
- 2002-08-01 WO PCT/US2002/024323 patent/WO2003014075A2/en active IP Right Grant
- 2002-08-01 BR BR0211698-7A patent/BR0211698A/pt not_active IP Right Cessation
- 2002-08-01 KR KR10-2004-7001505A patent/KR20040019094A/ko not_active Application Discontinuation
- 2002-08-01 AU AU2002324582A patent/AU2002324582B9/en not_active Ceased
- 2002-08-01 TW TW091117313A patent/TWI242555B/zh active
- 2002-08-01 PL PL02372212A patent/PL372212A1/xx unknown
- 2002-08-01 MX MXPA04001014A patent/MXPA04001014A/es active IP Right Grant
- 2002-08-01 EP EP02759233A patent/EP1492765B1/en not_active Expired - Lifetime
- 2002-08-01 US US10/210,829 patent/US6683091B2/en not_active Expired - Fee Related
- 2002-08-01 AR ARP020102926A patent/AR034390A1/es unknown
-
2004
- 2004-01-21 CO CO04003799A patent/CO5550419A2/es not_active Application Discontinuation
- 2004-03-03 NO NO20040933A patent/NO20040933L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1492765B1 (en) | 2011-07-06 |
BR0211698A (pt) | 2004-11-09 |
EP1492765A2 (en) | 2005-01-05 |
WO2003014075A3 (en) | 2004-09-30 |
PL372212A1 (en) | 2005-07-11 |
CN1630651A (zh) | 2005-06-22 |
MXPA04001014A (es) | 2004-05-27 |
HUP0600673A2 (en) | 2006-12-28 |
IL159848A0 (en) | 2004-06-20 |
CA2455863A1 (en) | 2003-02-20 |
CN1304390C (zh) | 2007-03-14 |
JP2005504760A (ja) | 2005-02-17 |
AU2002324582B2 (en) | 2006-01-05 |
US6683091B2 (en) | 2004-01-27 |
ATE515495T1 (de) | 2011-07-15 |
TWI242555B (en) | 2005-11-01 |
KR20040019094A (ko) | 2004-03-04 |
NO20040933L (no) | 2004-03-03 |
AU2002324582B9 (en) | 2006-02-16 |
HUP0600673A3 (en) | 2011-08-29 |
US20030135044A1 (en) | 2003-07-17 |
RU2004106540A (ru) | 2005-07-27 |
AR034390A1 (es) | 2004-02-25 |
WO2003014075A2 (en) | 2003-02-20 |
JP4418671B2 (ja) | 2010-02-17 |
CA2455863C (en) | 2010-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5550419A2 (es) | Novedosos inhibidores de la gama secretasa | |
FR18C1006I1 (fr) | Derives de quinoline ayant un groupe azolyle et derives de quinazoline | |
HUP0101624A2 (hu) | Új szubsztituált amidok, előállításuk és alkalmazásuk | |
CY1107005T1 (el) | Ετεροπολυκυκλικες ενωσεις και οι χρησεις τους ως ανταγωνιστες των μεταβοτροπικων υποδοχέων του γλουταμικου | |
WO2007064914A3 (en) | 5-(arylsulfonyl)-pyrazolopiperidines | |
ES2176329T3 (es) | Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos. | |
BR0016878A (pt) | Inibidores tricìclicos de cinases protéicas | |
EA200501730A1 (ru) | Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина | |
TNSN04165A1 (en) | Substituted hydroxyethylamines | |
EA200301100A1 (ru) | Новые фталазиноны | |
AR029214A1 (es) | Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza | |
MXPA04004477A (es) | Antagonistas del neuropeptido neuroquinina-1(nk1). | |
ATE513821T1 (de) | Thiadiazolin-derivate zur behandlung von krebs | |
WO2004030671A3 (en) | Use of 4-amino-quinazolines as anti cancer agents | |
DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
ATE239741T1 (de) | Derivate der phosphonsäure zur inhibierung von carboxypeptidase b | |
ECSP044970A (es) | Novedosos inhibidores de la gama secretasa | |
EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
HUP0301649A2 (hu) | Eljárás [(aza-cikloalkanoil)-amino]-tiazolok előállítására | |
BR0314461A (pt) | Processo para a preparação de derivado de 2-aminometilpiridina | |
PL353681A1 (en) | Applications of pyrrole derivatives in production of a drug | |
DE60204882D1 (de) | Zykloalkenylsulfonamidderivate | |
DE69910574D1 (de) | Pyrazolo[1,5-a]triazine als crf antagonisten | |
SI1603877T1 (sl) | Novi derivati aminopiridina kot antagonisti mGiuR5 | |
TR200201679T2 (tr) | Yeni heteroaril türevleri, bunların hazırlanması ve kullanımları. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |